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Current therapeutic strategies
According to the 2006 guidelines of the European
Society of Cardiology [16], therapeutic goals of
medical treatment of coronary heart disease can be
partitioned into (1) immediate short-term relieve, (2)
treatment aimed at relieve of symptoms, and (3)
treatment aimed at improving prognosis. Interest-
ingly, there is no overlap between drugs that improve
prognosis and drugs that relieve symptoms with the
exception of b-blockers after myocardial infarction.
This suggests that ischemia which causes symptoms
may not be a major mechanism relevant to prognosis,
whereas mechanisms which inﬂuence thrombocyte
function and anti-inﬂammatory or cytokine-neuro-
humoral actions may be beneﬁcial for survival.
Current strategies of drug-induced relieve of
symptoms aim to improve the imbalance between
oxygen supply of the heart and oxygen demand which
is relevant to myocardial ischemia and angina pec-
toris [16]. All agents in this category: b-blockers,
calcium channel antagonists, nitrates, K-channel
openers, and sinus node inhibitors reduce myocardial
oxygen demand. This occurs either by direct myo-
cardial effects or indirectly by complex effects on
hemodynamic determinants [13]. Calcium channel
antagonists, nitrates, and K-channel openers in
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j Abstract Myocardial ischemia is associated with reduced ATP ﬂuxes
and decreased energy supply resulting in disturbances of intracellular ion
homeostasis in cardiac myocytes. In the recent years, increased persistent
(late) sodium current was suggested to contribute to disturbed ion
homeostasis by elevating intracellular sodium concentration with
subsequent elevation of intracellular calcium. The new anti-ischemia
drug ranolazine, a speciﬁc inhibitor of late sodium current, reduces
sodium overload and hence ameliorates disturbed ion homeostasis. This
is associated with symptomatic improvement of angina in patients.
Moreover, ranolazine was shown to exhibit anti-arrhythmic effects. In the
present article, we review the relevant pathophysiological concepts for
the role of late sodium inhibition and summarize the most recent data
from basic as well as clinical studies.
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supply to the heart.
Ranolazine (Fig. 1), a piperazine derivative, is a
new anti-ischemic drug for the treatment of angina,
whose mode of action is different from the pharma-
cological principals mentioned above [3].
Pathophysiology of myocardial ischemia relevant
to the action of ranolazine
Myocardial ischemia immediately results in reduced
ATP ﬂuxes and reduced energy supply to various key
proteins for the contraction–relaxation cycle of the
individual cardiac myocyte. These include proteins
which control myocyte ion homeostasis. As a conse-
quence, intracellular sodium, and calcium concen-
tration are disturbed, which is relevant to myocardial
damage following ischemia.
There are several mechanisms by which energy
lack increases intracellular sodium (Fig. 2). A large
portion of the sodium enters the cell through the
cardiac sodium channel following depolarisation
during the initial phase (fast upstroke) of the action
potential. This sodium inﬂux causes further rapid
depolarisation leading to the activation of voltage-
gated L-type calcium channels causing calcium inﬂux.
Sodium channels spontaneously inactivate quickly
within one to three milliseconds. Channels recycle
and may be activated by the next membrane depo-
larisation [8, 22]. It has been shown that this typical
fast sodium current may be altered during patholog-
ical conditions such as hypoxia, exposure to ischemic
metabolites and reactive oxygen species. Under those
conditions, there is a pronounced late opening of the
sodium channel up to a few hundreds of milliseconds
following depolarisation referred to as late (or per-
sistent) sodium current (late INa, Fig. 3)[ 14, 28, 30,
31]. Late INa may represent a major source for in-
creased intracellular sodium during ischemia. Other
mechanisms leading to disturbed sodium balance
include sodium inﬂux through the sodium-proton
pump [7] or lack of sodium elimination through the
sodium potassium ATPase.
Energy lack and the resulting decrease in the phos-
phorylation potential reduce free energy available for
calcium transport into the sarcoplasmic reticulum and
therefore intracellular calcium accumulates in the
cytosol. As a consequence, elevated diastolic calcium
levelsactivatecontractileproteinseven duringdiastole
leading to diastolic dysfunction. Disturbed sarcoplas-
mic reticulum calcium accumulation is severely
aggravated by elevated intracellular sodium. This
mainly occurs through the sarcolemmal sodium–cal-
cium exchanger, which exchanges one calcium ion for
three sodium ions per cycle. The sodium–calcium ex-
changer can work in two different directions. In its
forward mode, it eliminates calcium outside of the cell
to accomplish diastolic relaxation (in addition to cal-
cium reuptake into the sarcoplasmic reticulum). In its
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Late INa inhibition with ranolazinereverse mode (usually during the action potential), it
brings in calcium into the cell in exchange to trans-
sarcolemmal elimination of sodium. The activity and
directionoftransportdependsontheabundanceofthe
protein as well as on the membrane potential, intra-
cellular sodium and intracellular calcium concentra-
tion. Sodium accumulation following myocardial
hypoxia (i.e., through late INa) promotes reverse mode
sodium–calcium exchange and therefore reduces the
overallcellularcapacitytoeliminatecalciumoutsideof
the cytosol. This adds to the elevated diastolic calcium
due to reduced sarcoplasmic reticulum calcium pump
activity and further aggravates diastolic dysfunction
due to contractile protein activation. Diastolic activa-
tion of contractile proteins is associated with extra
energy consumption [17]. Moreover, increased dia-
stolic tone increases micro-circulatory resistance and
further impairs energy balance of the ischemic myo-
cardium. Therefore, diastolic dysfunction following
myocardial ischemia increases energy consumption
and aggravates disturbed energy balance like a vicious
cycle.
Ranolazine has been shown to be a potent inhibitor
of late INa and therefore interrupts a major step in the
pathophysiology of myocardial ischemia [1].
Mode of action of ranolazine
In myocytes from dog and guinea pig hearts, ranol-
azine was shown to cause a concentration, voltage,
and frequency-dependent inhibition of late INa [1].
Ranolazine also was shown to prevent H2O2 induced
increase in late INa [25]. Most speciﬁcally, ranolazine
has been shown to reverse the sustained rise in dia-
stolic and systolic calcium caused by a well-known
enhancer of late INa, the sea anemone toxin ATX-II
[10, 26]. Taken together, the major mechanism of
action of ranolazine is to inhibit late INa thus pre-
venting sodium overload of the cell. As a conse-
quence, ranolazine prevents reverse mode sodium–
calcium exchange and thus diastolic accumulation of
calcium possibly resulting in improved diastolic tone
[12, 27] and improved coronary blood ﬂow [10].
Accordingly, ranolazine has been shown to decrease
post-ischemic contracture in rabbit isolated perfused
hearts subjected to ischemia and reperfusion [11].
As a late INa inhibitor, ranolazine was also shown to
increase action potential duration and thus modestly
QTintervalby2–5 ms[5,6].Thiseffect,however,isnot
heart rate-dependent and cannot be exaggerated dur-
ing bradycardia [2, 19, 32]. Furthermore, ranolazine
doesnotinduceearlyafterdepolarisationsanddoesnot
increase dispersion of repolarisation across the left
ventricular wall [2]. According to this proﬁle ranol-
azine does not increase the risk of Torsade de pointes
tachycardia as it is observed with many other QT
interval prolonging agents.
Clinical effects of ranolazine
Ranolazine has yet been studied in several clinical tri-
als. Three initial trials have investigated the efﬁcacy of
immediate release ranolazine [9, 20, 23]. Two larger
phase three studies have examined the efﬁcacy of sus-
tainedreleaseranolazineinpatientswithchronicstable
angina. MARISA (Monotherapy Assessment of Ranol-
azine In Stable Angina) randomised 191 patients to
placebo or ranolazine in a cross-over design with
1 week treatment period [6]. CARISA (Combination
Assessment of Ranolazine in Stable Angina) random-
ised patients to placebo or ranolazine on top of previ-
ous anti-anginal therapy. Treatment was maintained
for 12 weeks [5]. MARISA showed that ranolazine
monotherapy signiﬁcantly improved exercise perfor-
mance in patients with stable angina. This was true for
exercise duration, time to angina and time to 1 mm ST
segment depression. More speciﬁcally, 70% of patients
intheplacebogroupstoppedtheirexercisetestbecause
of angina as compared to only 52% in the ranolazine
group (1.5 g bidaily). CARISA improved peak and
trough exercise duration, time to angina and time to
1 mm ST depression. These effects were sustained
througha12-weektreatment. Also,ranolazinereduced
the number of angina attacks from a baseline of 4.5 per
week to 2.1 per week for ranolazine (1 g bidaily) com-
paredto3.3perweekforplacebo.Mostimportantly,the
anti-anginal effects of ranolazine in MARISA and
CARISA occurred without clinical meaningful changes
in heart rate or blood pressure.
In the MERLIN (Metabolic Efﬁciency with Ranol-
azine for Less Ischemia in Non-ST elevation acute
coronarysyndrome) TIMI-36 trial, theeffect of clinical
outcome of ranolazine therapy was studied in patients
with acute coronary syndromes [18]. MERLIN was a
multi-national, double-blind, randomised, placebo-
controlled, parallel-group clinical trial designed to
evaluate the efﬁcacy and safety of ranolazine during
acute and long-term treatment in 6560 patients with
non-ST elevation ACS treated with standard therapy.
Within 48 h of the onset of angina due to ACS, eligible
hospitalised patients were enrolled in the study and
randomised to receive intravenous ranolazine or pla-
cebo, followed by long-term treatment with ranolazine
tablets or placebo. Although ranolazine did not sig-
niﬁcantly inﬂuence the primary combined endpoint of
cardiovascular death, myocardial infarction or recur-
rent ischemia, additional analyses revealed a 13% rel-
ative reduction in the risk of recurrent ischemia.
Furthermore, ranolazine was favourable regarding
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mic effects of ranolzine became apparent [24]. This
underlines experimental data [4]. Thus inhibition of
late INa with ranolazine is safe in particular regarding
electrophysiological aspects. Although the results of
MERLINdonot support theuse of ranolazineforacute
management of ACS these ﬁndings support previous
ﬁndingregardingsafety and beneﬁtofranolazine asan
antianginal therapy and suggest a beneﬁt of ranolazine
asantianginaltherapyinabroadpopulationofpatients
with established ischemic heart disease.
Future aspects for clinical application for
ranolazine
Inhibition of enhanced late INa by ranolazine may
represent a new treatment option for cardiac diseases
associated with disturbed myocardial ion homeosta-
sis. Elevated intracellular sodium has been observed
in human heart failure and in several animal failure
models [15, 21]. It has been shown recently that in-
creased intracellular sodium in heart failure may, in
part, result from CaMKII-dependent phosphorylation
of sodium channels with subsequent increase in late
INa [29]. Therefore, ranolazine may be an interesting
approach for the treatment of systolic heart failure by
improving disturbed sodium homeostasis. Moreover,
calcium overload subsequent to disturbed sodium
homeostasis may also be a major pathophysiological
factor in diastolic heart failure. Therefore we specu-
late that in diastolic heart failure due to disturbed
sodium/calcium homeostasis, ranolazine may repre-
sent a new attractive treatment option. Accordingly,
studies in heart failure with systolic and diastolic
dysfunction are warranted to test the potential ther-
apeutical beneﬁt of ranolazine.
j Acknowledgements G.H. and L.S.M. are funded by the Deutsche
Forschungsgemeinschaft (DFG) through grants for a Clinical Re-
search group (MA 1982/2-1), L.S.M. in addition by a DFG Emmy
Noether-grant (MA 1982/1-5). Conflict of interest: All authors have
a collaboration/grant with CV Therapeutics.
References
1. Antzelevitch C, Belardinelli L, Zygmunt
AC et al (2004) Electrophysiological
effects of ranolazine, a novel antian-
ginal agent with antiarrhythmic prop-
erties. Circulation 110:904–910
2. Antzelevitch C, Belardinelli L, Zygmunt
AC et al (2004) Electrophysiological
effects of ranolazine, a novel antian-
ginal agent with antiarrhythmic prop-
erties. Circulation 110:904–910
3. Belardinelli L, Antzelevitch C, Fraser H
(2004) Inhibition of late (sustained/
persistent) sodium current: a potential
drug target to reduce intracellular so-
dium-dependent calcium overload and
its detrimental effects on cardiomyo-
cyte function. Europ Heart J 6(Suppl
I):13–17
4. Burashnikov A, Di Diego JM, Zygmunt
AC, Belardinelli L, Antzelevitch C
(2007) Atrium-selective sodium chan-
nel block as a strategy for suppression
of atrial ﬁbrillation: differences in so-
dium channel inactivation between at-
ria and ventricles and the role of
ranolazine. Circulation. 116:1449–1457
5. Chaitman BR, Pepine CJ, Parker JO
et al (2004) Effects of ranolazine with
atenolol, alodipine, or diltiazem on
exercise tolerance and angina fre-
quency in patients with severe chronic
angina: a randomized controlled trial. J
Am Med Assoc 291:309–316
6. Chaitman BR, Skettino SL, Parker JO
et al (2004) Anti-ischemic effects and
long-term survivial during ranolazine
monotherapy in patients with chronic
severe angina. J Am Coll Cardiol
43:1375–1382
7. Clanachan AS (2004) Assessment of
Ranolazine’s Effects on Mechanical
Function and [Ca
2+]i Accumulation in
Ejecting Rat Hearts (CVT Technical
Report Number CVT303.093-P)
8. Clancy CE, Kass RS (2002) Defective
cardiac ion channels: from mutations
to clinical syndromes. J Clin Invest
110:1075–1077
9. Cocco G, Rousseau MF, Bouvy T et al
(1992) Effects of a new mebatolic
modulator, ranolazine on exercise tol-
erance in angina pectoris patients
treated with beta-blocker or diltiazem.
J Cardiovasc Pharmacol 20:131–138
10. Fraser H, Belardinelli L, Wang L, Light
PE, McVeigh JJ, Clanachan ASD (2006)
Ranolazine decreases diastolic calcium
accumulation caused by ATX-II or
ischemia in rat hearts. J Mol Cell Car-
diol 41:1031–1038
11. Gralinski MR, Black SC, Kilgore KS
et al (1994) Cardioprotective effects of
ranolazine (RS-43285) in the isolated
perfused rabbit heart. Cardiovasc Res
28:1231–1237
12. Hayashida W, van Eyll C, Rousseau
MF, Pouleur H (1994) Effects of ranol-
azine on left ventricular regional dia-
stolic function in patients with
ischemic heart disease. Cardiovasc
Drugs Ther 8:741–747
13. Heusch G, Schulz R (2001) Perfusion-
contraction match and mismatch. Basic
Res Cardiol 96:1–10
14. Ju YK, Saint DA, Gage PW. (1996)
Hypoxia increases persistent sodium
current in rat ventricular myocytes. J
Physiol 497(Pt2):337–347
15. Maier LS, Hasenfuss G (2006) Role of
[Na
+]i and the emerging involvement
of the late Na current (INa,late) in the
pathophysiology of cardiovascular dis-
ease. Europ Heart J 8(Suppl A):A6–A9
16. Messerli FH, Mancia G, Conti CR, Pe-
pine CJ (2006) Eur Heart J 27(23):2902–
2903
17. Meyer M, Keweloh B, Guth K, Holmes
JW, Pieske B, Lehnart SE, Just H, Ha-
senfuss G (1998) Frequency-depen-
dence of myocardial energetics in
failing human myocardium as quanti-
ﬁed by a new method for the mea-
surement of oxygen consumption in
muscle strip preparations. J Mol Cell
Cardiol 30(8):1459–1470
G. Hasenfuss and L.S. Maier 225
Late INa inhibition with ranolazine18. Morrow DA, Scirica BM, Kar-
watoswska-Prokopczuk E, Murphy SA,
Budaj A, Varshavsky S, Wolff A, Skene
A, McCabes CH, Braunwald E (2007)
Effects of Ranolazine on recurrent
cardiovascular events in patients with
non-ST-elevation acute coronary syn-
dromes. The MERLIN-TIMI 36 Ran-
domized Trial. JAMA 297(16):1775–
1783
19. Okada Y, Ogawa S, Sadanaga T et al
(1996) Assessment of reverse use-
dependent blocking actions of class III
antiarrhythmic drugs by 24-h Holter
electrocardiography. J Am Coll Cardiol
27:84–89
20. Pepine CJ, Wolff AA (1999) A con-
trolled trial with a novel anti-ischemic
agent, ranolazine, in chronic stable
angina pectoris that is responsive to
conventional antianginal agents. Am J
Cardiol 84:46–50
21. Pieske B, Maier LS, Piacentino V III,
Weisser J, Hasenfuss G, Houser S
(2002) Rate dependence of [Na
+]i and
contractility in nonfailing and failing
human myocardium. Circulation
106:447–453
22. Roden DM (2001) Cardiac membrane
and action potentials. In: Spooner PM,
Rosen MR et al. (eds) foundations of
cardiac arrhythmias: basic concepts
and clinical approaches. Marcel Dek-
ker, New York, p. 21
23. Rousseau MF, Visser FG, Bax JJ (1994)
Ranolazine: antianginal therapy with a
novel mechanism: placebor controlled
comparison versus atenolol. Eur Heart
J 15(Suppl):95
24. Scirica BM, Morrow DA, Hod H, Mur-
phy SA, Belardinelli L, Hedgepeth CM,
Molhoek P, Verheugt FW, Gersh BJ,
McCabe CH, Braunwald E (2007) Effect
of Ranolazine, an Antianginal Agent
With Novel Electrophysiological Prop-
erties, on the Incidence of Arrhythmias
in Patients With Non ST-Segment Ele-
vation Acute Coronary Syndrome: Re-
sults From the Metabolic Efﬁciency
With Ranolazine for Less Ischemia in
Non ST-Elevation Acute Coronary
Syndrome Thrombolysis in Myocardial
Infarction 36 (MERLIN-TIMI 36) Ran-
domized Controlled Trial. Circulation
116(15):1647–1652
25. Song Y, Shryock JC, Wagner S, Maier
LS, Belardinelli L (2006) Blocking late
sodium current reduces hydrogen per-
oxide-induced arrhythmogenic activity
and contractile dysfunction. J Phar-
macol Exp Ther 318:214–222
26. Song Y, Shryock JC, Wu L et al (2004)
Antagonism by ranolazine of the
proarrhythmic effects of increasing late
INa in guinea pig ventricular myocytes.
J Cardiovasc Pharmacol 44:192–199
27. Sossalla S, Rasenack ECL, Wagner S,
Ruff H, Tenderich G, Hasenfuss G,
Belardinelli L, Maier LS (2007) Inhibi-
tion of late sodium current by ranol-
azine improves diastolic dysfunction in
human heart failure. Z Kardiol
96(Suppl 1):P837
28. Undrovians AI, Fleidervish IA, Ma-
kielski JC (1992) Inward sodium cur-
rent at resting potentials in single
cardiac myocytes induced by the
ischemic metabolite lysophosphatidyl-
choline. Circ Res 71:1231–1241
29. Wagner S, Dybkova N, Rasenack ECL,
Jacobshagen C, Fabritz L, Kirchhof P,
Maier SKG, Zhang T, Hasenfuss G,
Heller Brown J, Bers DM, Maier LS
(2006) Ca/calmodulin-dependent pro-
tein kinase II regulates cardiac Na
channels. J Clin Invest. 116:3127–3138
30. Ward CA, Giles WR.(1997) Ionic
mechanism of the effects of hydrogen
peroxide in rat ventricular myocytes. J
Physiol 500(Pt 3):631–642
31. Wu J, Corr PB. (1994) Palmitoyl cari-
tine modiﬁes sodium currents and in-
duces transient inward current in
ventricular myocytes. Am J Physiol
266:H1034–H1046
32. Wu L, Shryock JC, Song Y et al (2004)
Antiarrhythmic effects of ranolazine in
a guinea pig in vitro model of long-QT
syndrome. J Pharmacol Exp Ther
310:599–605
226 Clinical Research in Cardiology, Volume 97, Number 4 (2008)
 Steinkopff Verlag 2007